Chimera strategically minimizes biological risk for its high-tech protein degrader platform by targeting STAT6. This intracellular target is downstream of the IL-4/IL-13 receptors, the same pathway proven by the blockbuster biologic Dupixent. This balances novel technology risk with a well-understood mechanism of action, appealing to investors and potential partners.

Step Pharma's synthetic lethality approach targets two redundant enzymes in the same pathway. Deleting one makes cancer cells entirely dependent on the other. This direct dependency is harder for biology to circumvent compared to approaches targeting different, interconnected pathways, creating a "cleaner" kill mechanism.

The degradation mechanism is fundamentally superior to inhibition because it removes the entire protein, addressing both its enzymatic and scaffolding functions. This allows degraders to hit targets harder and more completely, suggesting they could become the dominant modality across oncology and other therapeutic areas.

Zelenorstat inhibits NMT, an enzyme that attaches a "GPS tag" to proteins, guiding them within the cell. By blocking this process, it renders key cancer-driving proteins useless, effectively confusing the cancer's operating system rather than using brute-force poison like chemotherapy.

Unlike traditional small molecules that need a pocket on a target protein, molecular glues work by changing the surface of an E3 ligase. This modified surface then perfectly matches and binds the target protein, enabling its degradation without requiring a direct drug-to-target binding site.

Cancer should be viewed not just as rogue cells, but as a complex system with its own supply chains and communication infrastructure. This perspective shift justifies novel therapies like Zelenorstat, which aim to dismantle this entire operating system by cutting its power source.

Even when an ARPI is no longer effective as a standalone therapy, continuing it may be beneficial. By maintaining pressure on the androgen receptor pathway, the drug can upregulate downstream targets like PSMA, potentially enhancing the efficacy of subsequent PSMA-targeted therapies like radioligands or ADCs.

Traditional targeted cancer therapies inhibit or 'cool down' overactive pathways, like pumping brakes on a runaway car. Delpha Therapeutics employs a counterintuitive 'activation lethality' approach, further over-activating pathways to 'overheat the engine' and cause catastrophic failure in cancer cells—a fundamentally opposite but highly effective strategy.

A single degrader molecule can destroy thousands of target proteins per hour, a massive improvement over the 1-to-1 stoichiometry of traditional inhibitors. This extreme potency makes them ideal payloads for Degrader-Antibody Conjugates (DACs), combining the precision of antibodies with the power of catalytic degradation.